| Year |
Citation |
Score |
| 2014 |
Falchook GS, Wheler JJ, Naing A, Jackson EF, Janku F, Hong D, Ng CS, Tannir NM, Lawhorn KN, Huang M, Angelo LS, Vishwamitra D, Hess K, Howard AN, Parkhurst KL, et al. Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: a phase I trial of bortezomib plus bevacizumab. Oncotarget. 5: 10280-92. PMID 25373733 DOI: 10.18632/Oncotarget.2163 |
0.3 |
|
| 2014 |
Schroeder RD, Angelo LS, Kurzrock R. NF2/merlin in hereditary neurofibromatosis 2 versus cancer: biologic mechanisms and clinical associations. Oncotarget. 5: 67-77. PMID 24393766 DOI: 10.18632/Oncotarget.1557 |
0.47 |
|
| 2013 |
Jiang Y, Janku F, Subbiah V, Angelo LS, Naing A, Anderson PM, Herzog CE, Fu S, Benjamin RS, Kurzrock R. Germline PTPRD mutations in Ewing sarcoma: biologic and clinical implications. Oncotarget. 4: 884-9. PMID 23800680 DOI: 10.18632/Oncotarget.1021 |
0.49 |
|
| 2013 |
Janku F, Huang HJ, Angelo LS, Kurzrock R. A kinase-independent biological activity for insulin growth factor-1 receptor (IGF-1R) : implications for inhibition of the IGF-1R signal. Oncotarget. 4: 463-73. PMID 23531874 DOI: 10.18632/Oncotarget.886 |
0.455 |
|
| 2013 |
Angelo LS, Maxwell DS, Wu JY, Sun D, Hawke DH, McCutcheon IE, Slopis JM, Peng Z, Bornmann WG, Kurzrock R. Binding partners for curcumin in human schwannoma cells: biologic implications. Bioorganic & Medicinal Chemistry. 21: 932-9. PMID 23294827 DOI: 10.1016/J.Bmc.2012.12.008 |
0.44 |
|
| 2013 |
Huang HJ, Devogelaere B, Falchook GS, Fu S, Angelo LS, Hong DS, Piha-Paul SA, Naing A, Holley VR, Tsimberidou AM, Stepanek VMT, Kim K, Subbiah V, Wheler JJ, Zinner R, et al. BRAF mutation testing with a novel, rapid, fully automated molecular diagnostics prototype platform. Journal of Clinical Oncology. 31: 11086-11086. DOI: 10.1200/Jco.2013.31.15_Suppl.11086 |
0.377 |
|
| 2013 |
Janku F, Angelo LS, Devogelaere B, Fachook GS, Fu S, Huang HJ, Tsimberidou AM, Hong DS, Stepanek VM, Holley VR, Routbort MJ, Sablon E, Maertens G, Kurzrock R. Abstract 4126: BRAF mutation testing with a novel, rapid, fully-automated molecular diagnostics prototype platform. Cancer Research. 73: 4126-4126. DOI: 10.1158/1538-7445.Am2013-4126 |
0.448 |
|
| 2011 |
Subbiah V, Slopis JM, Hong DS, Angelo LS, McCutcheon IE, Kurzrock R. Treatment of patients with advanced neurofibromatosis type 2 (NF2) with novel molecularly targeted therapies. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 2100. PMID 28020002 DOI: 10.1200/Jco.2011.29.15_Suppl.2100 |
0.398 |
|
| 2011 |
Huang HJ, Angelo LS, Rodon J, Sun M, Kuenkele KP, Parsons HA, Trent JC, Kurzrock R. R1507, an anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, and EWS/FLI-1 siRNA in Ewing's sarcoma: convergence at the IGF/IGFR/Akt axis. Plos One. 6: e26060. PMID 22022506 DOI: 10.1371/Journal.Pone.0026060 |
0.449 |
|
| 2011 |
Subbiah V, Angelo LS, Kurzrock R. Insulin-like growth factor 1 receptor (IGF-1R) inhibitor: another arrow in the quiver - Will it hit the moving target? Expert Opinion On Investigational Drugs. 20: 1471-7. PMID 21936711 DOI: 10.1517/13543784.2011.619978 |
0.468 |
|
| 2011 |
Angelo LS, Wu JY, Meng F, Sun M, Kopetz S, McCutcheon IE, Slopis JM, Kurzrock R. Combining curcumin (diferuloylmethane) and heat shock protein inhibition for neurofibromatosis 2 treatment: analysis of response and resistance pathways. Molecular Cancer Therapeutics. 10: 2094-103. PMID 21903608 DOI: 10.1158/1535-7163.Mct-11-0243 |
0.474 |
|
| 2009 |
Angelo LS, Kurzrock R. Target validation using Phase 0 clinical trials: Promises and pitfalls. Cancer Biology & Therapy. 8: 2010-2. PMID 20037466 DOI: 10.4161/Cbt.8.21.10154 |
0.41 |
|
| 2009 |
Gong J, Yang DJ, Kohanim S, Angelo LS, Kurzrock R. Molecular imaging of gefitinib activity in an epidermal growth factor receptor (EGFR)-bearing xenograft model. Cancer Biology & Therapy. 8: 2239-47. PMID 19823028 DOI: 10.4161/Cbt.8.23.9986 |
0.477 |
|
| 2009 |
Wu JY, Yang DJ, Angelo LS, Kohanim S, Kurzrock R. Molecular imaging of Bcr-Abl phosphokinase in a xenograft model. Molecular Cancer Therapeutics. 8: 703-10. PMID 19258427 DOI: 10.1158/1535-7163.Mct-08-0656 |
0.437 |
|
| 2009 |
Angelo LS, Kurzrock R. Turmeric and green tea: a recipe for the treatment of B-chronic lymphocytic leukemia. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 1123-5. PMID 19228716 DOI: 10.1158/1078-0432.Ccr-08-2791 |
0.357 |
|
| 2007 |
Hong DS, Angelo LS, Kurzrock R. Interleukin-6 and its receptor in cancer: Implications for translational therapeutics Cancer. 110: 1911-1928. PMID 17849470 DOI: 10.1002/Cncr.22999 |
0.402 |
|
| 2007 |
Angelo LS, Kurzrock R. Vascular endothelial growth factor and its relationship to inflammatory mediators. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 2825-30. PMID 17504979 DOI: 10.1158/1078-0432.Ccr-06-2416 |
0.431 |
|
| 2002 |
Angelo LS, Talpaz M, Kurzrock R. Autocrine interleukin-6 production in renal cell carcinoma: evidence for the involvement of p53. Cancer Research. 62: 932-40. PMID 11830554 |
0.322 |
|
| 1995 |
Owen-Schaub LB, Angelo LS, Radinsky R, Ware CF, Gesner TG, Bartos DP. Soluble Fas/APO-1 in tumor cells: a potential regulator of apoptosis? Cancer Letters. 94: 1-8. PMID 7542559 DOI: 10.1016/0304-3835(95)03834-J |
0.32 |
|
| Show low-probability matches. |